Valeo Pharma(VPHIF)
$0.050.00 (0.00%)
VPHIF
Valeo Pharma financials statements
$0.05
At close:0.00 (0.00%)
Valeo Pharma (VPHIF) Ratios
14 Followers
Valeo Pharma Ratios
VPHIF's free cash flow for Q3 2024 was C$451.00K. For the 2024 fiscal year, VPHIF's free cash flow was increased by C$0.00 and operating cash flow was C$451.00K. See a summary of the company’s cash flow.
| Ratios | Oct 23 | Oct 22 | Jan 22 | Jan 21 | Jan 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.25 | 2.64 | 0.81 | 1.26 | 0.37 |
| Quick Ratio | 0.74 | 1.99 | 0.30 | 1.06 | 0.24 |
| Cash Ratio | 0.37 | 1.47 | 0.13 | 0.66 | 0.07 |
| Solvency Ratio | -0.31 | -0.32 | -0.73 | -0.55 | -0.60 |
| Operating Cash Flow Ratio | -0.77 | -1.86 | -0.80 | -1.24 | -0.52 |
| Short-Term Operating Cash Flow Coverage | -3.41 | -38.36 | -2.54 | 0.00 | 0.00 |
| Net Current Asset Value | C$ -56.30M | C$ -35.58M | C$ -6.63M | C$ -2.48M | C$ -4.18M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.58 | 1.05 | 0.36 | 0.30 | 0.17 |
| Debt-to-Equity Ratio | -1.62 | -3.44 | 3.74 | 1.06 | -45.50 |
| Debt-to-Capital Ratio | 2.62 | 1.41 | 0.79 | 0.52 | 1.02 |
| Long-Term Debt-to-Capital Ratio | 3.14 | 1.43 | 0.44 | 0.49 | 1.02 |
| Financial Leverage Ratio | -1.02 | -3.26 | 10.24 | 3.57 | -263.95 |
| Debt Service Coverage Ratio | -0.62 | -2.07 | -1.77 | -6.25 | -33.96 |
| Interest Coverage Ratio | -1.25 | -3.03 | -9.45 | -7.26 | -32.23 |
| Debt to Market Cap | 5.09 | 1.12 | 0.11 | 0.06 | 0.02 |
| Interest Debt Per Share | 0.92 | 0.84 | 0.13 | 0.07 | 0.02 |
| Net Debt to EBITDA | -5.06 | -2.42 | -0.51 | -0.11 | -0.20 |
| Profitability Margins | |||||
| Gross Profit Margin | 24.26% | 22.64% | 29.17% | 18.49% | 21.30% |
| EBIT Margin | -26.00% | -61.80% | -83.96% | -55.73% | -53.29% |
| EBITDA Margin | -21.13% | -58.03% | -80.95% | -50.05% | -51.85% |
| Operating Profit Margin | -31.96% | -70.66% | -94.54% | -58.14% | -53.90% |
| Pretax Profit Margin | -51.58% | -97.03% | -104.99% | -63.73% | -54.96% |
| Net Profit Margin | -51.58% | -92.80% | -104.99% | -63.73% | -54.96% |
| Continuous Operations Profit Margin | -51.58% | -92.80% | -104.99% | -63.73% | -54.96% |
| Net Income Per EBT | 100.00% | 95.64% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 161.41% | 137.32% | 111.05% | 109.62% | 101.97% |
| Return on Assets (ROA) | -67.48% | -44.19% | -67.68% | -43.43% | -62.25% |
| Return on Equity (ROE) | 68.94% | 144.25% | -693.28% | -155.13% | 16431.82% |
| Return on Capital Employed (ROCE) | -82.30% | -45.67% | -225.02% | -64.97% | -266.54% |
| Return on Invested Capital (ROIC) | -67.29% | -42.88% | -120.97% | -64.37% | -266.54% |
| Return on Tangible Assets | -94.24% | -60.18% | -98.22% | -79.15% | -185.67% |
| Earnings Yield | -221.88% | -47.84% | -24.18% | -8.97% | -6.67% |
| Efficiency Ratios | |||||
| Receivables Turnover | 8.21 | 5.11 | 9.20 | 7.40 | 14.68 |
| Payables Turnover | 10.23 | 5.74 | 1.31 | 1.80 | 1.35 |
| Inventory Turnover | 3.99 | 2.15 | 1.25 | 6.91 | 9.23 |
| Fixed Asset Turnover | 20.24 | 12.31 | 6.33 | 12.35 | 22.22 |
| Asset Turnover | 1.31 | 0.48 | 0.64 | 0.68 | 1.13 |
| Working Capital Turnover Ratio | 3.58 | 2.50 | -14.64 | -8.82 | -2.72 |
| Cash Conversion Cycle | 100.35 | 177.57 | 53.18 | -100.38 | -206.22 |
| Days of Sales Outstanding | 44.45 | 71.41 | 39.69 | 49.30 | 24.86 |
| Days of Inventory Outstanding | 91.59 | 169.71 | 291.75 | 52.81 | 39.56 |
| Days of Payables Outstanding | 35.68 | 63.55 | 278.25 | 202.49 | 270.65 |
| Operating Cycle | 136.04 | 241.12 | 331.43 | 102.11 | 64.42 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.18 | -0.35 | -0.18 | -0.09 | -0.05 |
| Free Cash Flow Per Share | -0.25 | -0.44 | -0.23 | -0.12 | -0.07 |
| Dividend Paid and CapEx Coverage Ratio | -2.83 | -4.14 | -3.55 | -3.77 | -2.44 |
| Capital Expenditure Coverage Ratio | -2.83 | -4.14 | -3.55 | -3.77 | -2.44 |
| Operating Cash Flow Coverage Ratio | -0.24 | -0.46 | -1.61 | -1.62 | -2.30 |
| Operating Cash Flow to Sales Ratio | -0.29 | -1.03 | -0.91 | -0.71 | -0.35 |
| Free Cash Flow Yield | -169.54% | -65.77% | -26.81% | -12.63% | -6.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.45 | -2.09 | -4.14 | -11.15 | -14.99 |
| Price-to-Sales (P/S) Ratio | 0.23 | 1.94 | 4.34 | 7.10 | 8.24 |
| Price-to-Book (P/B) Ratio | -0.31 | -3.02 | 28.67 | 17.29 | -2462.74 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.59 | -1.52 | -3.73 | -7.92 | -16.66 |
| Price-to-Operating Cash Flow Ratio | -0.80 | -1.89 | -4.78 | -10.02 | -23.49 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.03 | -0.03 | -0.87 | -0.33 |
| Enterprise Value Multiple | -6.16 | -5.76 | -5.88 | -14.31 | -16.08 |
| Enterprise Value | 70.20M | 92.75M | 64.48M | 53.49M | 54.85M |
| EV to EBITDA | -6.16 | -5.76 | -5.88 | -14.31 | -16.08 |
| EV to Sales | 1.30 | 3.34 | 4.76 | 7.16 | 8.34 |
| EV to Free Cash Flow | -3.30 | -2.62 | -4.09 | -7.98 | -16.87 |
| EV to Operating Cash Flow | -4.47 | -3.25 | -5.24 | -10.10 | -23.77 |
| Tangible Book Value Per Share | -0.60 | -0.41 | -0.06 | -0.03 | -0.08 |
| Shareholders’ Equity Per Share | -0.47 | -0.22 | 0.03 | 0.05 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.04 | 0.00 | 0.00 | -0.09 |
| Revenue Per Share | 0.63 | 0.34 | 0.19 | 0.13 | 0.13 |
| Net Income Per Share | -0.32 | -0.32 | -0.20 | -0.08 | -0.07 |
| Tax Burden | 1.00 | 0.96 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.98 | 1.57 | 1.25 | 1.14 | 1.03 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.42 | 0.68 | 0.98 | 0.44 | 0.46 |
| Stock-Based Compensation to Revenue | 0.02 | 0.03 | 0.07 | 0.06 | 0.05 |
| Income Quality | 0.56 | 1.11 | 0.87 | 1.11 | 0.64 |
Currency in CAD
